By analyzing TAMs isolated from other CNS gliomas, we observed that CD44+ TAMs were also present in GBM, showing a similar expression pattern as those in ependymoma, although they hardly existed in gliomas, indicating that TAM-targeting immunotherapy strategies based on these dual-function TAMs are applicable to multiple types of tumors but not all neurological tumors. The gene discussed is CD44; the disease is glioma.